Elderly People — Virtual Gait System Intervention in Older People
Citation(s)
Aitkens M A legacy of surgeons. Minn Med. 1988 Oct;71(10):592-6.
Dushanova J, Donoghue J Neurons in primary motor cortex engaged during action observation. Eur J Neurosci. 2010 Jan;31(2):386-98. doi: 10.1111/j.1460-9568.2009.07067.x. Epub 2010 Jan 13.
Jeannerod M The hand and the object: the role of posterior parietal cortex in forming motor representations. Can J Physiol Pharmacol. 1994 May;72(5):535-41. Review.
Nguyen L, Murphy K, Andrews G Cognitive and neural plasticity in old age: A systematic review of evidence from executive functions cognitive training. Ageing Res Rev. 2019 Aug;53:100912. doi: 10.1016/j.arr.2019.100912. Epub 2019 May 30.
Onishi H [The current status and future of prosthetic joint replacement]. Kango Gijutsu. 1988 Oct;34(13):1566-71. Japanese.
Sudarsky L Gait disorders: prevalence, morbidity, and etiology. Adv Neurol. 2001;87:111-7. Review.
Vigneswaran G, Philipp R, Lemon RN, Kraskov A M1 corticospinal mirror neurons and their role in movement suppression during action observation. Curr Biol. 2013 Feb 4;23(3):236-43. doi: 10.1016/j.cub.2012.12.006. Epub 2013 Jan 3.
Effectiveness of Virtual Gait System Intervention in Motor Function in Older People.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
